Search Results 921-930 of 15355 for alt

1. A Study to Evaluate the Safety and Effectiveness of Obeticholic Acid Treatment on People with Non-Alcoholic Steatohepatitis with Fibrosis - Mayo Clinic

   ALT >1.5× upper limit of normal (ULN). For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for ...

2. A Study to Assess the Effectiveness, Safety and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 Inflammation - Mayo Clinic

   Alanine transaminase (ALT) > 3 times upper limit of normal range (ULN);; Hemoglobin < 10g /100 mL for male and < 9g/ 100 mL for female;; Platelets < 100 000 ...

3. A Study Of The Effectiveness And Safety Of Targeted Delivery Of Auto CD34+ Stem Cells Into Heart Muscle For Improving Exercise Capacity In People With Angina Resistant To Treatment - Mayo Clinic

   Hepatic dysfunction as evidenced by elevated AST or ALT levels > 2.5 x ULN; Any previous transplant requiring immunosuppression; Disease state requiring ...

4. ALSENLITE: Senolytics for Alzheimer's Disease - Mayo Clinic

   AST/ALT > 2.5x upper limit normal 14. Presence of significant liver disease with total bilirubin > 2X upper limit or as per clinical judgment 15. Inability ...

5. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC) - Mayo Clinic

   ... ALT/AST \>3x ULN. For patients with hepatic metastases, ALT/AST \>5x ULN is exclusionary. 11. INR or PT or aPTT \> 1.8 × ULN, unless the participant is ...

6. A Study to Evaluate the Effect of 1,25-Dihydroxyvitamin D3 to Treat Insulin Secretion and Muscle Strength in Pre-diabetics - Mayo Clinic

   Chronic active liver disease (bilirubin > 1.2 mg/dL, AST > 144 IU/L, or ALT > 165 IU/L). History of chronic hepatitis. History of depression, anxiety or ...

7. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Participation eligibility · AST or ALT > 2.5 x ULN; · Total bilirubin ≥ 1.5 x ULN; · INR > 1.5 x ULN in the absence of therapeutic anticoagulation; · PTT or aPTT > ...

8. A Study of to Evaluate Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer - Mayo Clinic

   AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN. Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional ...

9. Actinium Therapy For Late-stage Aggressive Sarcomas - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN. 6. Calculated creatinine clearance ≥ 60 mL/min. 6. Coagulation parameters ...

10. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

    Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5 x ULN. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN ...